Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV

Lignende værker

• Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes
  af: Landersdorfer, Cornelia B, et al.
  Udgivet: (2012)
• Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes
  af: He, Yan-Ling, et al.
  Udgivet: (2010)
• Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
  af: Mistry, Goutam C, et al.
  Udgivet: (2008)
• Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males
  af: Herman, Gary A, et al.
  Udgivet: (2011)
• The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
  af: Chakraborty, Sandeep, et al.
  Udgivet: (2015)